University Hospital Santiago de Compostela
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pico, Maria Luz Couce
NCT05933200 / 2022-001539-10: A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD

Active, not recruiting
3
60
Europe, Japan, RoW
Triheptanoin, UX007, Dojolvi, MCT Oil, Medium-chain Triglyceride
Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc.
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
09/26
09/26
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT05526066 / 2021-001081-38: Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Active, not recruiting
2
24
Europe
ARCT-810, Placebo
Arcturus Therapeutics, Inc., Arcturus Therapeutics, Inc.
Ornithine Transcarbamylase Deficiency, OTC Deficiency, OTCD
12/24
03/25
Wierzba, Jolanta
NCT05933200 / 2022-001539-10: A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD

Active, not recruiting
3
60
Europe, Japan, RoW
Triheptanoin, UX007, Dojolvi, MCT Oil, Medium-chain Triglyceride
Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc.
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
09/26
09/26

Download Options